<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01658514</url>
  </required_header>
  <id_info>
    <org_study_id>LCRM101</org_study_id>
    <nct_id>NCT01658514</nct_id>
  </id_info>
  <brief_title>Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction</brief_title>
  <official_title>A Randomized, Crossover Study Assessing the Single Dose Pharmacokinetics of Delayed-Release Metformin in Subjects With Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elcelyx Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elcelyx Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in
      subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction,
      or severe kidney dysfunction. The safety and tolerability of Met DR was also examined. In
      addition, this study compared the behavior of a single dose of Met DR with that of
      extended-release metformin (Met XR) and placebo in subjects with the varying levels of kidney
      function described above.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (0-t) of Plasma Metformin</measure>
    <time_frame>from the time of dosing (0 h) to 72 hours postdose</time_frame>
    <description>AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Plasma Metformin</measure>
    <time_frame>from the time of dosing (0 h) to 72 hours postdose</time_frame>
    <description>Cmax = Maximum concentration from the time of dosing (0 h) to the time of the last quantifiable metformin concentration following dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration</measure>
    <time_frame>from the time of dosing (0 h) to 24 hours postdose</time_frame>
    <description>To determine the exposure-response relationship of metformin and plasma lactate concentrations</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Met DR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of 1000 mg metformin delayed-release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Met XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One dose of 1000 mg metformin extended-release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One dose of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Met DR</intervention_name>
    <description>metformin delayed-release tablets</description>
    <arm_group_label>Met DR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Met XR</intervention_name>
    <description>metformin extended-release tablets</description>
    <arm_group_label>Met XR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 80 (inclusive) years old at Visit 1 (Screening)

          2. Male, or female and met all of the following criteria:

               -  Not breastfeeding

               -  Negative pregnancy test result at Visit 1 (Screening) (not applicable to
                  postmenopausal or surgically sterile females)

               -  Surgically sterile, postmenopausal, or if of childbearing potential, practiced
                  and was willing to continue to practice appropriate birth control during the
                  entire duration of the study

               -  Body weight of ≥45 kg

          3. Body mass index (BMI) of 18.0 to 40.0 kg/m² (inclusive) at Visit 1 (Screening)

          4. Had type 2 diabetes mellitus and an HbA1c ≤10.0%

          5. Had a physical examination with no clinically significant abnormalities as judged by
             the investigator

          6. Estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m² based on the
             Modification of Diet in Renal Disease (MDRD) equation

          7. Ability to understand and willingness to adhere to protocol requirements

        Exclusion Criteria:

          1. Had End Stage Renal Disease requiring dialysis or severe renal dysfunction with eGFR
             &lt;15 mL/min/1.73 m²

          2. Was on dialysis or had been on dialysis within 12 months of Visit 1 (Screening)

          3. Had received or planned to receive any iodinated contrast dye within 1 week prior to
             Visit 1 (Screening) or after study medication administration

          4. Was taking or had taken within 1 week of Visit 1 cationic drugs that are eliminated by
             renal tubular secretion (e.g., amiloride, digoxin, morphine, procainamide, quinidine,
             quinine, ranitidine, triamterene, trimethoprim, and vancomycin)

          5. Had a clinically significant medical condition that could potentially affect study
             participation and/or personal well-being, as judged by the investigator, including but
             not limited to the following conditions:

               -  Hepatic disease

               -  Gastrointestinal disease

               -  Endocrine disorder (type 2 diabetes mellitus was allowed)

               -  Cardiovascular disease

               -  Central nervous system diseases

               -  Psychiatric or neurological disorders

               -  Organ transplantation

               -  Chronic or acute infection

               -  Orthostatic hypotension, fainting spells or blackouts

               -  Allergy or hypersensitivity

          6. Had any chronic disease requiring medication that had been adjusted in the past 14
             days (subjects could take acute intermittent over-the-counter medications such as
             Tylenol, if needed)

          7. Had major surgery of any kind within 6 months of Visit 1 (Screening)

          8. Had a clinically significant finding of an electrocardiogram (ECG) as assessed by the
             investigator at Visit 1 (Screening)

          9. Had clinical laboratory test (clinical chemistry, hematology, or urinalysis)
             abnormalities, other than those related to diabetes or renal disease and other stable
             diseases, judged by the investigator to be clinically significant at Visit 1
             (Screening)

         10. Had a hemoglobin result &lt;8 g/dL or a level indicating severe anemia of renal origin

         11. Had a physical, psychological, or historical finding that, in the investigator's
             opinion, would make the subject unsuitable for the study

         12. Had received Byetta® or short-acting insulin within 3 days of Visit 1 (Screening)

         13. Had received metformin within 4 weeks of Visit 1 (Screening)

         14. Had any drug treatment that affects gastrointestinal motility or gastric pH
             (prescription or over-the-counter), including any antacids or medications such as
             Rolaids or Pepcid, within 2 days of Visit 2

         15. Abused drugs or alcohol or had a history of abuse that in the investigator's opinion
             would cause the individual to be noncompliant with study procedures

         16. Smoked more than 10 cigarettes, 3 cigars, or 3 pipes per day

         17. Had donated blood within 2 months of Visit 1 (Screening) or was planning to donate
             blood during the study

         18. Had received any investigational drug within one month (or seven half-lives of the
             investigational drug, whichever was greater) of Visit 1 (Screening)

         19. Had known allergies or hypersensitivity to any component of study treatment

         20. Was employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract
             worker, or designee of the company)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Canas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prism Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Lasseter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology of Miami, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander White, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Progressive Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harold Bays, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisville Metabolic and Atherosclerosis Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Curtis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Compass Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prabir Roy-Chaudhury</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Veterans Affairs Medical Center Department of Internal Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sunder Mudaliar</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego Veterans Healthcare System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nelson Kopyt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northeast Clinical Research Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Bakris GL, Mudaliar, S, Kim T, Burns C, Skare S, Baron A, Fineman M. Effects of New Metformin Formulation in Stage 3 and 4 CKD: A Pilot Study. J Am Soc Nephrol. 2014; 25:549A.</citation>
  </results_reference>
  <results_reference>
    <citation>DeFronzo R, Fleming GA, Chen K, Bicsak TA. Corrigendum to &quot;Metformin-associated lactic acidosis: Current perspectives on causes and risk&quot; [Metabolism 65 (2016) 20-29]. Metabolism. 2016 Sep;65(9):1432-1433. doi: 10.1016/j.metabol.2016.05.014. Epub 2016 Jun 14.</citation>
    <PMID>27311500</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2012</study_first_submitted>
  <study_first_submitted_qc>August 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <results_first_submitted>October 12, 2015</results_first_submitted>
  <results_first_submitted_qc>November 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2015</results_first_posted>
  <last_update_submitted>November 25, 2015</last_update_submitted>
  <last_update_submitted_qc>November 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence ABC</title>
          <description>A = 1 dose of 1000 mg Met XR B = 1 dose of 1000 mg Met DR C = 1 dose of placebo
each treatment was separated by a wash out period of 2 to 10 days</description>
        </group>
        <group group_id="P2">
          <title>Sequence CAB</title>
          <description>A = 1 dose of 1000 mg Met XR B = 1 dose of 1000 mg Met DR C = 1 dose of placebo
each treatment was separated by a wash out period of 2 to 10 days</description>
        </group>
        <group group_id="P3">
          <title>Sequence BCA</title>
          <description>A = 1 dose of 1000 mg Met XR B = 1 dose of 1000 mg Met DR C = 1 dose of placebo
each treatment was separated by a wash out period of 2 to 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment A</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment B</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment C</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started - Normal RF Cohort Only</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed - Normal RF Cohort Only</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started - Mild RI Cohort Only</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed - Mild RI Cohort Only</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started - Moderate RI Cohort Only</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed - Moderate RI Cohort Only</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started - Severe RI Cohort Only</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed - Severe RI Cohort Only</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Population - All subjects were to receive all interventions and are distributed in this module according to their renal function cohort to inform PK analyses comparing these populations</population>
      <group_list>
        <group group_id="B1">
          <title>Normal</title>
          <description>Normal Renal Function = eGFR ≥90 mL/min/1.73 m²</description>
        </group>
        <group group_id="B2">
          <title>Mild RI</title>
          <description>Mild Renal Impairment = eGFR ≥60 to &lt;90 mL/min/1.73 m²</description>
        </group>
        <group group_id="B3">
          <title>Moderate RI</title>
          <description>Moderate Renal Impairment = eGFR ≥30 to &lt;60 mL/min/1.73 m²</description>
        </group>
        <group group_id="B4">
          <title>Severe RI</title>
          <description>Severe Renal Impairment = eGFR ≥15 to &lt;30 mL/min/1.73 m²</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="11.01"/>
                    <measurement group_id="B2" value="60.8" spread="6.62"/>
                    <measurement group_id="B3" value="72.6" spread="3.90"/>
                    <measurement group_id="B4" value="70.5" spread="5.50"/>
                    <measurement group_id="B5" value="65.1" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.9" spread="18.02"/>
                    <measurement group_id="B2" value="94.9" spread="12.06"/>
                    <measurement group_id="B3" value="94.2" spread="14.96"/>
                    <measurement group_id="B4" value="99.8" spread="10.69"/>
                    <measurement group_id="B5" value="95.7" spread="13.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="3.81"/>
                    <measurement group_id="B2" value="31.8" spread="3.79"/>
                    <measurement group_id="B3" value="30.4" spread="3.33"/>
                    <measurement group_id="B4" value="33.3" spread="4.09"/>
                    <measurement group_id="B5" value="31.9" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-t) of Plasma Metformin</title>
        <description>AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration</description>
        <time_frame>from the time of dosing (0 h) to 72 hours postdose</time_frame>
        <population>PK Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Met DR</title>
            <description>One dose of 1000 mg Metformin Delayed-Release</description>
          </group>
          <group group_id="O2">
            <title>Met XR</title>
            <description>One dose of 1000 mg Metformin Extended-Release</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t) of Plasma Metformin</title>
          <description>AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration</description>
          <population>PK Evaluable Population</population>
          <units>ng*h/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal (N = 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5362" spread="943"/>
                    <measurement group_id="O2" value="10411" spread="1831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild RI (N = 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8705" spread="1368"/>
                    <measurement group_id="O2" value="11788" spread="1853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate RI (N = 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11477" spread="1915"/>
                    <measurement group_id="O2" value="20240" spread="3377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe RI (N = 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22893" spread="4307"/>
                    <measurement group_id="O2" value="43683" spread="8218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Normal Renal Function Cohort. Met XR is the denominator for the % ratio of LS means and the comparator for the p-values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>p-values &lt;0.10 are considered statistically significant</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Included treatment, renal group, sequence, period and treatment*renal group as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>% Ratio of LS Means</param_type>
            <param_value>51.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.77</ci_lower_limit>
            <ci_upper_limit>70.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Mild RI Renal Function Cohort. Met XR is the denominator for the % ratio of LS means and the comparator for the p-values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0733</p_value>
            <p_value_desc>p-values &lt;0.10 are considered statistically significant</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Included treatment, renal group, sequence, period and treatment*renal group as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>% Ratio of LS Means</param_type>
            <param_value>73.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.97</ci_lower_limit>
            <ci_upper_limit>97.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Moderate RI Renal Function Cohort. Met XR is the denominator for the % ratio of LS means and the comparator for the p-values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <p_value_desc>p-values &lt;0.10 are considered statistically significant</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Included treatment, renal group, sequence, period and treatment*renal group as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>% Ratio of LS Means</param_type>
            <param_value>56.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.25</ci_lower_limit>
            <ci_upper_limit>76.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Severe RI Cohort. Met XR is the denominator for the % ratio of LS means and the comparator for the p-values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <p_value_desc>p-values &lt;0.10 are considered statistically significant</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Included treatment, renal group, sequence, period and treatment*renal group as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>% Ratio of LS Means</param_type>
            <param_value>52.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.61</ci_lower_limit>
            <ci_upper_limit>73.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Plasma Metformin</title>
        <description>Cmax = Maximum concentration from the time of dosing (0 h) to the time of the last quantifiable metformin concentration following dose administration</description>
        <time_frame>from the time of dosing (0 h) to 72 hours postdose</time_frame>
        <population>PK Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Met DR</title>
            <description>One dose of 1000 mg Metformin Delayed-Release</description>
          </group>
          <group group_id="O2">
            <title>Met XR</title>
            <description>One dose of 1000 mg Metformin Extended-Release</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Plasma Metformin</title>
          <description>Cmax = Maximum concentration from the time of dosing (0 h) to the time of the last quantifiable metformin concentration following dose administration</description>
          <population>PK Evaluable Population</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal (N = 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="969" spread="153"/>
                    <measurement group_id="O2" value="1479" spread="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild RI (N = 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1036" spread="147"/>
                    <measurement group_id="O2" value="1340" spread="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate RI (N = 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="925" spread="139"/>
                    <measurement group_id="O2" value="1634" spread="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe RI (N = 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1414" spread="239"/>
                    <measurement group_id="O2" value="2590" spread="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Normal Renal Function Cohort. Met XR is the denominator for the % ratio of LS means and the comparator for the p-values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0474</p_value>
            <p_value_desc>p-values &lt;0.10 are considered statistically significant</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Included treatment, renal group, sequence, period and treatment*renal group as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>% Ratio of LS Means</param_type>
            <param_value>65.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>46.32</ci_lower_limit>
            <ci_upper_limit>92.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Mild RI Renal Function Cohort. Met XR is the denominator for the % ratio of LS means and the comparator for the p-values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1691</p_value>
            <p_value_desc>p-values &lt;0.10 are considered statistically significant</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Included treatment, renal group, sequence, period and treatment*renal group as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>% Ratio of LS Means</param_type>
            <param_value>77.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>56.72</ci_lower_limit>
            <ci_upper_limit>105.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Moderate RI Renal Function Cohort. Met XR is the denominator for the % ratio of LS means and the comparator for the p-values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <p_value_desc>p-values &lt;0.10 are considered statistically significant</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Included treatment, renal group, sequence, period and treatment*renal group as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>% Ratio of LS Means</param_type>
            <param_value>56.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.73</ci_lower_limit>
            <ci_upper_limit>78.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Severe RI Renal Function Cohort. Met XR is the denominator for the % ratio of LS means and the comparator for the p-values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0097</p_value>
            <p_value_desc>p-values &lt;0.10 are considered statistically significant</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Included treatment, renal group, sequence, period and treatment*renal group as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>% Ratio of LS Means</param_type>
            <param_value>54.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.68</ci_lower_limit>
            <ci_upper_limit>79.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration</title>
        <description>To determine the exposure-response relationship of metformin and plasma lactate concentrations</description>
        <time_frame>from the time of dosing (0 h) to 24 hours postdose</time_frame>
        <population>PD Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Met DR</title>
            <description>One dose of 1000 mg Metformin Delayed-Release</description>
          </group>
          <group group_id="O2">
            <title>Met XR</title>
            <description>One dose of 1000 mg Metformin Extended-Release</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration</title>
          <description>To determine the exposure-response relationship of metformin and plasma lactate concentrations</description>
          <population>PD Evaluable Population</population>
          <units>R²</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000011129"/>
                    <measurement group_id="O2" value="0.069527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9444</p_value>
            <p_value_desc>R² for Placebo-adjusted Change from Pre-dose Value in Lactate Versus Metformin Concentration</p_value_desc>
            <method>Pearson Correlation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>R² for placebo-adjusted change from pre-dose value in lactate versus metformin concentration</p_value_desc>
            <method>Pearson Correlation</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 19 to 76 days depending on the number of days before the start of Visits 2 and 3 and the number of washout days between the treatment visits.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>One dose of Placebo</description>
        </group>
        <group group_id="E2">
          <title>Met DR</title>
          <description>One dose of 1000 mg Metformin Delayed-Release</description>
        </group>
        <group group_id="E3">
          <title>Met XR</title>
          <description>One dose of 1000 mg Metformin Extended-Release</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel Puncture Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Infusion Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat Tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the Study may be published by INSTITUTE, however the publication shall not disclose any SPONSOR Confidential Information, the INSTITUTE shall send the SPONSOR a copy of any such proposed publication 90 days prior to submission for publication, the INSTITUTE, on request of the SPONSOR, shall delete any SPONSOR Confidential Information in the proposed publication, and the INSTITUTE shall, on the SPONSOR’s request, delay submission while the SPONSOR files applications for patents.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Development</name_or_title>
      <organization>Elcelyx Therapeutics, Inc</organization>
      <phone>858-876-1814</phone>
      <email>info@elcelyx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

